Cue Biopharma (CUE) Proxy Filing summary

Executive summary

• Special Meeting scheduled for October 8, 2024, to be held virtually for all stockholders of record as of September 5, 2024.

• Main agenda: vote on increasing authorized capital stock and common stock, and potential adjournment if more time is needed for solicitation.

• Proxy materials distributed by mail and email starting September 13, 2024.

Voting matters and shareholder proposals

• Proposal 1: Amend Certificate of Incorporation to increase authorized capital stock from 110,000,000 to 210,000,000 and common stock from 100,000,000 to 200,000,000.

• Proposal 2: Approve adjournment of the meeting if more time is needed to solicit votes for Proposal 1.

• Board recommends voting FOR both proposals.

• No other business will be conducted at the meeting.

• Deadlines and procedures for shareholder proposals for the 2025 annual meeting are outlined.

Board of directors and corporate governance

• Board approved the proposed amendment on August 27, 2024, and recommends its adoption.

• Board retains discretion to abandon the amendment if deemed not in the best interests of the company before filing.